Subscribe to our Email Alerts

Amplia Therapeutics Limited

Focal Adhesion Kinase: A New Target in the Fight Against Cancer

Learn more

Amplia Therapeutics Limited

Focus on Fibrotic Cancers and Fibrosis

Learn more

Amplia Therapeutics Limited

Amplia's ACCENT pancreatic cancer clinical trial is now recruiting

Learn more
 

A new approach for treating cancer and fibrotic diseases​

Amplia is a clinical-stage company developing small molecule inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases​.
To view the latest Amplia Therapeutics Limited's Investor Presentation click here Read More

Latest Presentations

read more

Latest ASX Announcements

read more

Media Releases

read more

ASX Share Price

Market Cap:
Price Delay ~20min
read more

Amplia's AMP945 clinical trial in pancreatic cancer, ACCENT, is now recruiting

Learn More
Amplia Therapeutics recognises and respects First Nations People and welcomes the work of all those who strive for health equality in Australia

Quick Links

Contact Us

Level 17, 350 Queen Street
Melbourne VIC 3000
Australia

info@ampliatx.com

 

Email Alerts

Subscribe to our Email Alerts

Copyright © Amplia Therapeutics Limited
Site Map Privacy Search
Site by